King's College London

Research portal

Factors influencing the choice of monoclonal antibodies for antibody–drug conjugates

Research output: Contribution to journalReview articlepeer-review

Original languageEnglish
Pages (from-to)354-361
Number of pages8
JournalDRUG DISCOVERY TODAY
Volume27
Issue number1
DOIs
PublishedJan 2022

Bibliographical note

Funding Information: The authors would like to thank the Commonwealth Scholarship Commission in the UK for supporting M.M.H. during his PhD studies. Publisher Copyright: © 2021 Elsevier Ltd Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

King's Authors

Abstract

In antibody–drug conjugates (ADCs), monoclonal antibodies (mAbs) act as carriers for a cytotoxic payload providing the therapy with targeted action against cells expressing a target cell surface antigen. An appropriate choice of mAb is crucial to developing a successful ADC for clinical development. However, problems such as immunogenicity, poor pharmacokinetic (PK) and pharmacodynamic(PD) profiles and variable drug–antibody ratios (DARs) plague ADCs. In this review, we detail recent mAb-based innovations and factors that should be considered to overcome these problems to achieve a new generation of more effective ADC therapeutics.

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454